Ir.madrigalpharma.com

Overview Madrigal Pharmaceuticals.

WEBA Company Focused on Improving Care for Patients with NASH. Madrigal is a biopharmaceutical company pursuing novel therapeutics for nonalcoholic steatohepatitis …

Actived: Just Now

URL: https://ir.madrigalpharma.com/

Madrigal Pharmaceuticals Presents New Data from the Phase 3 …

WEBMultiple resmetirom and Madrigal health economics outcomes research abstracts will be presented at the AASLD Liver Meeting: Oral presentation: “Relationship …

Category:  Health Go Health

Madrigal Pharmaceuticals Presents Five Health Economics …

WEBJesse Fishman, Senior Director, Health Economics and Outcomes Research at Madrigal, stated, “We are gaining important new insights about the serious risks and …

Category:  Health Go Health

Madrigal Pharmaceuticals Announces FDA Approval of Rezdiffra

WEBRezdiffra becomes the first and only medication approved by the FDA for the treatment of NASH (also known as “MASH”); Accelerated approval was based on Phase …

Category:  Health Go Health

Madrigal Announces Positive Topline Results from the Pivotal …

WEBIn MAESTRO-NASH, a 52-week serial liver biopsy Phase 3 study in more than 950 patients, resmetirom achieved both primary endpoints and potentially clinically …

Category:  Health Go Health

Madrigal Pharmaceuticals Announces Publication of the Phase 3 …

WEBResmetirom is the first investigational medicine for NASH to achieve fibrosis improvement and NASH resolution primary endpoints in a Phase 3 trial; Detailed …

Category:  Medicine Go Health

Madrigal Pharmaceuticals Completes Enrollment of the 52 Week …

WEBCONSHOHOCKEN, Pa., June 30, 2021 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) announced today achievement of the planned …

Category:  Health Go Health

Madrigal Pharmaceuticals Presents Late-Breaking Phase 3 NASH …

WEBLate-breaking data from the double-blind portion of the noninvasive Phase 3 MAESTRO NAFLD-1 study show resmetirom to be safe and well-tolerated and to reduce …

Category:  Health Go Health

Madrigal Pharmaceuticals Presents Phase 3 MAESTRO-NASH Data …

WEB* In the modified intent-to-treat (mITT) population, patients without a Week 52 biopsy are deemed nonresponders. New MAESTRO-NASH data being presented at …

Category:  Health Go Health

Madrigal Pharmaceuticals Presents New Data from the Phase …

WEBMultiple resmetirom and Madrigal health economics outcomes research abstracts will be presented at the AASLD Liver Meeting: Oral presentation: Relationship of Non-Invasive …

Category:  Health Go Health

Madrigal Pharmaceuticals Announces U.S. Availability of Rezdiffra

WEBNaim Alkhouri, MD, FAASLD, Chief Medical Officer, Chief of Transplant Hepatology, Director of the Fatty Liver Program, Arizona Liver Health, stated, “The …

Category:  Medical Go Health

Madrigal Pharmaceuticals Announces EMA Validation of its …

WEB“NASH with fibrosis represents a serious burden for both patients and health systems. Without treatment, the disease can lead to cirrhosis, liver failure, liver cancer and premature death,” said Becky Taub, M.D., Chief Medical Officer and President of Research & Development of Madrigal. “Based on the positive results from our Phase 3

Category:  Cancer,  Medical Go Health

Madrigal Pharmaceuticals Provides Corporate Updates and …

WEBPriority Review of resmetirom new drug application underway in the U.S.; Bill Sibold appointed Chief Executive Officer of Madrigal in September 2023; $500 million …

Category:  Health Go Health

Positive Topline Phase 3 MAESTRO-NAFLD-1 Data …

WEBCardiovascular Health January 31, 2022 Primary and key secondary endpoints from the double-blind placebo-controlled 969-patient MAESTRO-NAFLD-1 safety study were …

Category:  Health Go Health

Madrigal MAESTRO Phase 3 NASH Trials Continue without …

WEBThyroid hormone, through activation of its β-receptor in hepatocytes, plays a central role in liver function impacting a range of health parameters from levels of serum …

Category:  Health Go Health

Positive Topline Phase 3 MAESTRO-NAFLD-1 Data Demonstrate

WEBThyroid hormone, through activation of its β-receptor in hepatocytes, plays a central role in liver function impacting a range of health parameters from levels of serum …

Category:  Health Go Health

Madrigal’s MGL-3196 Achieves Primary Endpoint in Patients

WEBAmong its many functions in the human body, thyroid hormone, through activation of its beta receptor, plays a central role in controlling lipid metabolism, …

Category:  Health Go Health

Madrigal Pharmaceuticals Initiates the MAESTRO-NASH Outcomes …

WEBCONSHOHOCKEN, Pa., Aug. 31, 2022 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a clinical-stage biopharmaceutical company …

Category:  Health Go Health

Madrigal Pharmaceuticals Announces Support of Fatty Liver

WEBThe NAFLD Screening fund will be the catalyst for greater patient engagement in research and development, including treatment preparedness as new therapies …

Category:  Health Go Health

Madrigal Pharmaceuticals Highlights Presentations at The Liver …

WEB#1675 IMPROVEMENT OF HEALTH-RELATED QUALITY OF LIFE IS ASSOCIATED WITH IMPROVEMENT OF FAT FRACTION BY MRI-PDFF IN …

Category:  Health Go Health

Madrigal Pharmaceuticals Announces the Initiation of a Phase 2 …

WEB-- Study expected to provide proof-of-concept data in NASH for the first liver-directed, thyroid hormone receptor (THR) ß-selective agonist –-- Primary endpoint is the …

Category:  Health Go Health

Madrigal Pharmaceuticals Presents Five Health Economics …

WEBJesse Fishman , Senior Director, Health Economics and Outcomes Research at Madrigal, stated, We are gaining important new insights about the serious risks and complications …

Category:  Health Go Health